This highlights that whilst clinicians are looking favourably at insulin delivery pumps as a therapeutic intervention for patients, there is either a lack of funding, lack of access to technology by the NHS Trust as a whole, lack of resources in diabetes services to meet demand in a timely manner, or potential delays in the referral process [31]. This evidence concerns the gene INS and diabetes mellitus.